BRPI0810064B8 - compostos contendo nitrogênio tricíclico como agentes antibacterianos, composições farmacêuticas que compreendem os ditos compostos e uso dos mesmos para o tratamento de infecções bacterianas em mamíferos - Google Patents

compostos contendo nitrogênio tricíclico como agentes antibacterianos, composições farmacêuticas que compreendem os ditos compostos e uso dos mesmos para o tratamento de infecções bacterianas em mamíferos

Info

Publication number
BRPI0810064B8
BRPI0810064B8 BRPI0810064A BRPI0810064A BRPI0810064B8 BR PI0810064 B8 BRPI0810064 B8 BR PI0810064B8 BR PI0810064 A BRPI0810064 A BR PI0810064A BR PI0810064 A BRPI0810064 A BR PI0810064A BR PI0810064 B8 BRPI0810064 B8 BR PI0810064B8
Authority
BR
Brazil
Prior art keywords
compounds
mammals
antibacterial agents
treatment
pharmaceutical compositions
Prior art date
Application number
BRPI0810064A
Other languages
English (en)
Portuguese (pt)
Inventor
Joseph Hennessy Alan
Evan Davies David
Thomas Davies David
Giordano Ilaria
David Pearson Neil
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39580226&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0810064(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0707705A external-priority patent/GB0707705D0/en
Priority claimed from GB0720569A external-priority patent/GB0720569D0/en
Priority claimed from GB0805311A external-priority patent/GB0805311D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of BRPI0810064A2 publication Critical patent/BRPI0810064A2/pt
Publication of BRPI0810064B1 publication Critical patent/BRPI0810064B1/pt
Publication of BRPI0810064B8 publication Critical patent/BRPI0810064B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/16—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
BRPI0810064A 2007-04-20 2008-04-16 compostos contendo nitrogênio tricíclico como agentes antibacterianos, composições farmacêuticas que compreendem os ditos compostos e uso dos mesmos para o tratamento de infecções bacterianas em mamíferos BRPI0810064B8 (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB0707705A GB0707705D0 (en) 2007-04-20 2007-04-20 Compounds
GB0707705.0 2007-04-20
GB0720569A GB0720569D0 (en) 2007-10-19 2007-10-19 Compounds
GB0720569.3 2007-10-19
GB0805311.8 2008-03-20
GB0805311A GB0805311D0 (en) 2008-03-20 2008-03-20 Compounds
PCT/EP2008/054621 WO2008128942A1 (en) 2007-04-20 2008-04-16 Tricyclic nitrogen containing compounds as antibacterial agents

Publications (3)

Publication Number Publication Date
BRPI0810064A2 BRPI0810064A2 (pt) 2019-08-27
BRPI0810064B1 BRPI0810064B1 (pt) 2021-03-30
BRPI0810064B8 true BRPI0810064B8 (pt) 2021-05-25

Family

ID=39580226

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0810064A BRPI0810064B8 (pt) 2007-04-20 2008-04-16 compostos contendo nitrogênio tricíclico como agentes antibacterianos, composições farmacêuticas que compreendem os ditos compostos e uso dos mesmos para o tratamento de infecções bacterianas em mamíferos

Country Status (31)

Country Link
US (1) US8389524B2 (cg-RX-API-DMAC7.html)
EP (1) EP2137196B1 (cg-RX-API-DMAC7.html)
JP (1) JP5389013B2 (cg-RX-API-DMAC7.html)
KR (1) KR101567096B1 (cg-RX-API-DMAC7.html)
CN (1) CN101687887B (cg-RX-API-DMAC7.html)
AR (1) AR066111A1 (cg-RX-API-DMAC7.html)
AT (1) ATE483717T1 (cg-RX-API-DMAC7.html)
AU (1) AU2008240764C1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0810064B8 (cg-RX-API-DMAC7.html)
CA (1) CA2684659C (cg-RX-API-DMAC7.html)
CL (1) CL2008001122A1 (cg-RX-API-DMAC7.html)
CO (1) CO6251368A2 (cg-RX-API-DMAC7.html)
CR (2) CR11123A (cg-RX-API-DMAC7.html)
CY (1) CY1111248T1 (cg-RX-API-DMAC7.html)
DE (1) DE602008002912D1 (cg-RX-API-DMAC7.html)
DK (1) DK2137196T3 (cg-RX-API-DMAC7.html)
DO (1) DOP2009000240A (cg-RX-API-DMAC7.html)
EA (1) EA015821B1 (cg-RX-API-DMAC7.html)
HR (1) HRP20100574T1 (cg-RX-API-DMAC7.html)
IL (1) IL201204A0 (cg-RX-API-DMAC7.html)
MA (1) MA31324B1 (cg-RX-API-DMAC7.html)
MX (1) MX2009011317A (cg-RX-API-DMAC7.html)
MY (1) MY149347A (cg-RX-API-DMAC7.html)
NZ (1) NZ579877A (cg-RX-API-DMAC7.html)
PE (1) PE20090274A1 (cg-RX-API-DMAC7.html)
PL (1) PL2137196T3 (cg-RX-API-DMAC7.html)
PT (1) PT2137196E (cg-RX-API-DMAC7.html)
SI (1) SI2137196T1 (cg-RX-API-DMAC7.html)
TW (1) TWI431006B (cg-RX-API-DMAC7.html)
UY (1) UY31038A1 (cg-RX-API-DMAC7.html)
WO (1) WO2008128942A1 (cg-RX-API-DMAC7.html)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1954697T1 (sl) * 2005-10-21 2010-05-31 Glaxo Group Ltd Peri kondenzirane triciklične spojine uporabne kot antibakterijska sredstva
EP1847543A1 (de) 2006-04-19 2007-10-24 Boehringer Ingelheim Pharma GmbH & Co. KG Dihydrothienopyrimidine zur Behandlung von entzündlichen Erkrankungen
GB0608263D0 (en) 2006-04-26 2006-06-07 Glaxo Group Ltd Compounds
PT2215092E (pt) * 2007-10-19 2012-04-10 Boehringer Ingelheim Int Piperidino-di-hidrotienopirimidinas substituídas
WO2009050242A2 (de) 2007-10-19 2009-04-23 Boehringer Ingelheim International Gmbh Heterocyclus-substituierte piperazino-dihydrothienopyrimidine
ATE537175T1 (de) 2007-10-19 2011-12-15 Boehringer Ingelheim Int Neue piperazino-dihydrothienopyrimidin-derivate
CA2713182C (en) 2008-02-20 2016-09-13 Actelion Pharmaceuticals Ltd Azatricyclic antibiotic compounds
JP5474941B2 (ja) * 2008-05-23 2014-04-16 グラクソ グループ リミテッド 窒素含有三環式化合物およびその抗菌剤としての使用
WO2009141399A1 (en) * 2008-05-23 2009-11-26 Glaxo Group Limited Tricyclic nitrogen containing compounds and their use as antibacterials
HRP20150370T1 (hr) 2008-10-07 2015-05-08 Actelion Pharmaceuticals Ltd. Antibiotiäśki spojevi tricikliäśkog oksazolidinona
JP2012505866A (ja) * 2008-10-17 2012-03-08 グラクソ グループ リミテッド 抗菌剤として使用される三環式窒素化合物
US8653080B2 (en) 2009-01-14 2014-02-18 Salk Institute For Biological Studies Methods for screening and compounds that protect against amyloid diseases
AR076222A1 (es) 2009-04-09 2011-05-26 Actelion Pharmaceuticals Ltd Derivados 2-hidroxietil-1h-quinolin-ona y sus analogos azaisotericos con actividad antibacteriana y composiciones farmaceuticas que los contienen
TW201130854A (en) 2009-12-22 2011-09-16 Bayer Schering Pharma Ag Pyridinone derivatives and pharmaceutical compositions thereof
ES2834973T3 (es) 2010-05-04 2021-06-21 Alkermes Pharma Ireland Ltd Procedimiento de síntesis de compuestos de lactama oxidada
US20130059866A1 (en) 2011-08-24 2013-03-07 Boehringer Ingelheim International Gmbh Novel piperidino-dihydrothienopyrimidine sulfoxides and their use for treating copd and asthma
US9802954B2 (en) 2011-08-24 2017-10-31 Boehringer Ingelheim International Gmbh Piperidino-dihydrothienopyrimidine sulfoxides and their use for treating COPD and asthma
CN103113291B (zh) * 2013-02-04 2015-03-04 浙江大学 一种3位烯基吡啶衍生物的合成方法
WO2015012210A1 (ja) * 2013-07-23 2015-01-29 エーザイ・アール・アンド・ディー・マネジメント株式会社 ヘテロ縮合環化合物
BR112017003705B1 (pt) * 2014-08-22 2022-07-12 Glaxosmithkline Intellectual Property Development Limited Compostos contendo nitrogênio tricíclicos para o tratamento de infecção por neisseria gonorrhoea
JOP20180114B1 (ar) * 2016-06-22 2022-09-15 Univ Vanderbilt عوامل تعديل متباينة التجاسم موجبة من مستقبل الأسيتيل كولين المسكاريني m4
WO2018195098A1 (en) 2017-04-17 2018-10-25 Ohio State Innovation Foundation Type ii topoisomerase inhibitors and methods of making and using thereof
WO2020201833A1 (en) 2019-04-03 2020-10-08 Glaxomithkline Intellectual Property Development Limited Gepotidacin for use in the treatment of bacterial urinary tract infections
CA3143619A1 (en) * 2019-07-05 2021-01-14 Glaxosmithkline Intellectual Property Development Limited Combination for the treatment of infections caused by mycoplasma genitalium
BR112022018315A2 (pt) * 2020-04-02 2022-10-25 Glaxosmithkline Ip Dev Ltd Regime para tratar a infecção por neisseria gonorrhoeae com gepotidacina
JP7682923B2 (ja) * 2020-04-29 2025-05-26 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド ゲポチダシンの結晶形態
CN111494241B (zh) * 2020-06-01 2023-03-24 湖北洁世达环保科技有限公司 一种纸巾柔润保湿液
BR112023015676A2 (pt) * 2021-02-05 2023-10-17 Glaxosmithkline Ip Dev Ltd Formulações orais em dose sólida
CA3240991A1 (en) 2022-01-21 2023-07-27 Nicole SCANGARELLA-OMAN Gepotidacin and vancomycin for use in the treatment of an infection caused by staphylococcus saprophyticus
EP4316463A1 (en) 2022-08-02 2024-02-07 GlaxoSmithKline Intellectual Property Development Limited Novel formulation
JP2025532252A (ja) 2022-09-26 2025-09-29 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド 処置方法

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6403610B1 (en) * 1999-09-17 2002-06-11 Aventis Pharma S.A. Quinolylpropylpiperidine derivatives, their preparation and the compositions which comprise them
US6525049B2 (en) * 2000-07-05 2003-02-25 Pharmacia & Upjohn Company Pyrroloquinolones as antiviral agents
US6624159B2 (en) * 2000-07-12 2003-09-23 Pharmacia & Upjohn Company Heterocycle carboxamides as antiviral agents
CN1452619A (zh) * 2000-07-26 2003-10-29 史密斯克莱·比奇曼公司 具有抗细菌活性的氨基哌啶喹啉和它们的氮杂等排的类似物
US6603005B2 (en) * 2000-11-15 2003-08-05 Aventis Pharma S.A. Heterocyclylalkylpiperidine derivatives, their preparation and compositions containing them
GB0031088D0 (en) * 2000-12-20 2001-01-31 Smithkline Beecham Plc Medicaments
WO2002050036A1 (en) * 2000-12-21 2002-06-27 Ciba Speciality Chemicals Holding Inc. Crystalline forms of cerivastatin sodium
GB0101577D0 (en) 2001-01-22 2001-03-07 Smithkline Beecham Plc Compounds
US6602884B2 (en) * 2001-03-13 2003-08-05 Aventis Pharma S.A. Quinolylpropylpiperidine derivatives, their preparation, and compositions containing them
GB0112834D0 (en) 2001-05-25 2001-07-18 Smithkline Beecham Plc Medicaments
GB0112836D0 (en) * 2001-05-25 2001-07-18 Smithkline Beecham Plc Medicaments
GB0118238D0 (en) * 2001-07-26 2001-09-19 Smithkline Beecham Plc Medicaments
AU2002350217A1 (en) * 2001-12-04 2003-06-17 Bristol-Myers Squibb Company Glycinamides as factor xa inhibitors
US7312212B2 (en) * 2002-01-29 2007-12-25 Glaxo Group Limited Aminopiperidine derivatives
US7109213B2 (en) * 2002-01-29 2006-09-19 Glaxo Group Limited Aminopiperidine compounds, process for their preparation, and pharmaceutical compositions containing them
TW200409637A (en) * 2002-06-26 2004-06-16 Glaxo Group Ltd Compounds
TW200406413A (en) * 2002-06-26 2004-05-01 Glaxo Group Ltd Compounds
GB0217294D0 (en) * 2002-07-25 2002-09-04 Glaxo Group Ltd Medicaments
FR2844268B1 (fr) * 2002-09-11 2004-10-22 Aventis Pharma Sa Derives de la quinolyl propyl piperidine, leurs procedes et intermediaires de preparation et les compositions qui les contiennent
FR2844270B1 (fr) * 2002-09-11 2006-05-19 Aventis Pharma Sa Derives de la quinolyl propyl piperidine, leur procede et intermediaires de preparation et les compositions qui les contiennent
ATE463494T1 (de) * 2002-10-10 2010-04-15 Morphochem Ag Komb Chemie Neue verbindungen mit antibakterieller aktivität
AU2003303956A1 (en) * 2002-11-05 2004-11-23 Smithkline Beecham Corporation Antibacterial agents
US7618959B2 (en) * 2002-11-05 2009-11-17 Smithklinebeecham Corp Antibacterial agents
TW200427688A (en) * 2002-12-18 2004-12-16 Glaxo Group Ltd Antibacterial agents
TW200507841A (en) * 2003-03-27 2005-03-01 Glaxo Group Ltd Antibacterial agents
US7232833B2 (en) * 2003-03-28 2007-06-19 Novexel 4-substituted quinoline derivatives, method and intermediates for their preparation and pharmaceutical compositions containing them
DE10316081A1 (de) * 2003-04-08 2004-10-21 Morphochem AG Aktiengesellschaft für kombinatorische Chemie Neue Verbindungen mit antibakterieller Aktivität
US7348434B2 (en) * 2003-08-08 2008-03-25 Antony Bigot 4-substituted quinoline derivatives, method and intermediates for their preparation and pharmaceutical compositions containing them
FR2867472B1 (fr) 2004-03-12 2008-07-18 Aventis Pharma Sa Derives de quinoleines-4-substituees, leurs procede et intermediaires de preparation et les compositions pharmaceutiques qui les contiennent
EP1796466A4 (en) * 2004-06-15 2009-09-02 Glaxo Group Ltd ANTIBACTERIAL AGENTS
FR2872164B1 (fr) * 2004-06-29 2006-11-17 Aventis Pharma Sa Derives de quinoleines-4-substituees, leur procede et intermediaires de preparation et les compositions pharmaceutiques qui les contiennent
JP2008505920A (ja) 2004-07-08 2008-02-28 グラクソ　グループ　リミテッド 抗菌剤
US20080194547A1 (en) * 2004-07-09 2008-08-14 Glaxo Group Limited Antibacterial Agents
WO2006017326A1 (en) * 2004-07-13 2006-02-16 Glaxo Group Limited Antibacterial agents
WO2006012396A1 (en) 2004-07-22 2006-02-02 Glaxo Group Limited Antibacterial agents
WO2006017468A2 (en) * 2004-08-02 2006-02-16 Glaxo Group Limited Antibacterial agents
US20070161627A1 (en) * 2004-08-09 2007-07-12 Miller William H Antibacterial agents
DE102004041163A1 (de) * 2004-08-25 2006-03-02 Morphochem Aktiengesellschaft für kombinatorische Chemie Neue Verbindungen mit antibakterieller Aktivität
CA2580621A1 (en) 2004-09-24 2006-03-30 Actelion Pharmaceuticals Ltd New bicyclic antibiotics
JP2008515796A (ja) * 2004-10-05 2008-05-15 アクテリオン ファーマシューティカルズ リミテッド 新規なピペリジン系抗生物質
WO2006046552A1 (ja) 2004-10-27 2006-05-04 Toyama Chemical Co., Ltd. 新規な含窒素複素環化合物およびその塩
US7709472B2 (en) * 2005-01-25 2010-05-04 Glaxo Group Limited Antibacterial agents
US7648980B2 (en) * 2005-01-25 2010-01-19 Glaxo Group Limited Antibacterial agents
US7605169B2 (en) * 2005-01-25 2009-10-20 Glaxo Group Limited Antibacterial agents
WO2006081289A2 (en) * 2005-01-25 2006-08-03 Glaxo Group Limited Antibacterial agents
EP1846418A4 (en) * 2005-01-25 2009-12-23 Glaxo Group Ltd ANTIBACTERIAL ACTIVE SUBSTANCES
WO2006099884A1 (en) 2005-03-24 2006-09-28 Actelion Percurex Ag Beta-aminoalcohol antibiotics
NZ562034A (en) 2005-03-31 2009-10-30 Janssen Pharmaceutica Nv Bicyclic pyrazole compounds as antibacterial agents
JP2008542249A (ja) * 2005-05-24 2008-11-27 アストラゼネカ アクチボラグ 抗細菌活性を持つアミノピペリジンキノリン及びそのアザ等立体類似体
CN101180298B (zh) * 2005-05-25 2011-04-27 埃科特莱茵药品有限公司 抗生素衍生物
MY150958A (en) * 2005-06-16 2014-03-31 Astrazeneca Ab Compounds for the treatment of multi-drug resistant bacterial infections
EP1900732A4 (en) * 2005-06-24 2009-11-18 Toyama Chemical Co Ltd NEW NITROGENATED HETEROCYCLIC COMPOUND AND SALT THEREOF
SI1954697T1 (sl) * 2005-10-21 2010-05-31 Glaxo Group Ltd Peri kondenzirane triciklične spojine uporabne kot antibakterijska sredstva
US20070185153A1 (en) * 2005-12-22 2007-08-09 Nathalie Cailleau Compounds
JP2009532504A (ja) * 2006-04-06 2009-09-10 グラクソ グループ リミテッド 抗菌薬
ATE481406T1 (de) * 2006-04-06 2010-10-15 Glaxo Group Ltd Pyrrolochinoxalinonderivate als antibakterielle mittel
GB0608263D0 (en) * 2006-04-26 2006-06-07 Glaxo Group Ltd Compounds
US20100256124A1 (en) * 2006-06-09 2010-10-07 David Thomas Davies Substituted 1-Methyl-1H-Quinolin-2-Ones And 1-Methyl-1H-1,5-Naphthyridin-2-Ones As Antibacterials
GB0613208D0 (en) * 2006-07-03 2006-08-09 Glaxo Group Ltd Compounds
EP1992628A1 (en) * 2007-05-18 2008-11-19 Glaxo Group Limited Derivatives and analogs of N-ethylquinolones and N-ethylazaquinolones
GB0705672D0 (en) * 2007-03-23 2007-05-02 Glaxo Group Ltd Compounds
EP1980251A1 (en) * 2007-04-13 2008-10-15 Glaxo Group Limited Pyrrolo[3,2,1-ij]quinoline-4-one derivatives for treating tuberculosis
GB0707706D0 (en) * 2007-04-20 2007-05-30 Glaxo Group Ltd Compounds
GB0707708D0 (en) * 2007-04-20 2007-05-30 Glaxo Group Ltd Compounds
EP2005995A1 (en) * 2007-06-22 2008-12-24 Glaxo Group Limited Heterocyclic compounds for the treatment of tuberculosis
GB0800367D0 (en) * 2008-01-09 2008-02-20 Glaxo Group Ltd Compounds

Also Published As

Publication number Publication date
TW200848420A (en) 2008-12-16
KR101567096B1 (ko) 2015-11-06
AU2008240764B2 (en) 2011-04-07
HRP20100574T1 (hr) 2010-12-31
DOP2009000240A (es) 2009-12-31
AR066111A1 (es) 2009-07-22
ATE483717T1 (de) 2010-10-15
UY31038A1 (es) 2008-11-28
PL2137196T3 (pl) 2011-03-31
US20100137282A1 (en) 2010-06-03
NZ579877A (en) 2011-09-30
EA015821B1 (ru) 2011-12-30
CN101687887A (zh) 2010-03-31
DK2137196T3 (da) 2011-01-10
CN101687887B (zh) 2012-08-29
MX2009011317A (es) 2009-11-05
CA2684659A1 (en) 2008-10-30
US8389524B2 (en) 2013-03-05
WO2008128942A1 (en) 2008-10-30
JP2010524884A (ja) 2010-07-22
BRPI0810064A2 (pt) 2019-08-27
EP2137196B1 (en) 2010-10-06
CR11123A (es) 2010-03-08
BRPI0810064B1 (pt) 2021-03-30
CY1111248T1 (el) 2015-06-11
CL2008001122A1 (es) 2008-10-24
SI2137196T1 (sl) 2011-01-31
TWI431006B (zh) 2014-03-21
CO6251368A2 (es) 2011-02-21
HK1138000A1 (en) 2010-08-13
MY149347A (en) 2013-08-30
MA31324B1 (fr) 2010-04-01
IL201204A0 (en) 2010-05-17
PT2137196E (pt) 2010-12-16
CA2684659C (en) 2015-11-24
EP2137196A1 (en) 2009-12-30
CR20150586A (es) 2016-04-04
KR20100017133A (ko) 2010-02-16
EA200970987A1 (ru) 2010-04-30
DE602008002912D1 (de) 2010-11-18
AU2008240764C1 (en) 2011-10-20
PE20090274A1 (es) 2009-04-03
JP5389013B2 (ja) 2014-01-15
AU2008240764A1 (en) 2008-10-30

Similar Documents

Publication Publication Date Title
BRPI0810064B8 (pt) compostos contendo nitrogênio tricíclico como agentes antibacterianos, composições farmacêuticas que compreendem os ditos compostos e uso dos mesmos para o tratamento de infecções bacterianas em mamíferos
UY30759A1 (es) Compuestos quimicos
UY31673A1 (es) "derivados heterocíclicos de urea y métodos de uso de los mismos-211"
UY32158A (es) Derivados heterociclicos y metodos de uso de los mismos
UY32315A (es) Compuestos de piperidina y usos de los mismo-596
EA033311B1 (ru) Производные бензоксаборола в качестве антибактериальных средств
UY30544A1 (es) Compuestos de pirrolo-piperidina y sales farmacéuticametne aceptables de los mismos, procesos de fabricacion, composiciones y aplicaciones
BRPI0821004A8 (pt) Composto derivado de aminopirazol, composição farmacêutica que o contem e uso deste
UY31141A1 (es) Compuestos de piperidina y sus usos
CL2011000729A1 (es) Compuestos derivados de metanopirazolo[3,4-e][1,3]diazepin; procedimiento de preparacion; composicion farmaceutica que los comprende; y su uso en el tratamiento de infecciones bacterianas.
UY31860A (es) Piridinas de tiazolo como inhibidoras de la adn girasa
BR112012017473A2 (pt) pirido(1,2-a) pirimidinas, seu uso, bem como composição farmacêutica compreendendo tais compostos
CL2011000116A1 (es) Compuestos derivados de imidazo[1,2-a]piridina; procedimiento de preparacion; composicion farmaceutica; compuestos intermediarios; y uso en el tratamiento del cancer.
CL2007001711A1 (es) Compuestos derivados de pirazolopiridina sustituida;composicion farmaceutica que los comprende;metodo de preparacion de los compuestos ,compuestos intermediarios;y su uso en el tratamiento de enfermedades,tales como tumores,artritis reumatoide,enfermedades del crecimiento vascular desregulado, entre otras.
BR112014003063A2 (pt) "3,4-di-hidro-1h-[1,8]naftiridinonas substituídas com ciclopenta[c]pirrol antibacterianas, composição farmacêutica compreendendo os referidos compostos, processos para preparação destes e uso".
SV2010003752A (es) Derivados de urea heterociclicos para el tratamiento de infecciones bacterianas
GT200600520A (es) Agentes antibacterianos
DOP2010000374A (es) Derivados heterociclicos de la urea y sus metodos de empleo
BR112014002958A2 (pt) "3,4-di-hidro-1h-[1,8]naftiridinonas substituídas com piperidinila antibacterianas, composição farmacêutica compreendendo os referidos compostos, processos para preparação destes e uso".
UY32674A (es) Derivados heterociclicos de la urea y sus metodos de empleo
UY32856A (es) Derivados heterocíclicos de urea y métodos de uso de los mismos
CL2009001267A1 (es) Compuestos derivados de triciclos nitrogenados, con actividad antibacteriana; procedimiento de preparacion; composicion farmceutica que los comprende; para el tratamiento de la tuberculosis.
UY32694A (es) Derivados heterocíclicos de urea y métodos de uso de los mismos
UY32316A (es) Derivados de piperidina utiles en el tratamiento de infecciones bacterianas
AR072426A1 (es) Uso de nifurtimox para el tratamiento de enfermedades causadas por tricomonadida

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 30/03/2021, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 16/04/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B25G Requested change of headquarter approved

Owner name: GLAXO GROUP LIMITED (GB)